NTT
18.10.2021 08:17:10 CEST | Business Wire | Press release
WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT. The survey focuses on the role of business in contributing to societal goals.
WSJ Intelligence conducted a survey of 351 CEOs of large corporations representing ten key industries in 15 countries to understand their views on their organization’s role in society, social impact strategies, the stakeholders involved, and how the Covid-19 pandemic has driven these strategies.
The research confirms that post-pandemic people and the planet rather than solely profit are becoming increasingly important for organizations of all sizes. While this trend was evident before March 2020, the pandemic brought it to the forefront.
The latest research considers, too, how organizations better support employee wellbeing and change management. It uncovers the most valuable tools and tips for social purpose implementation while also analyzing the most significant challenges.
Key Findings:
- 94% agree that “The pandemic has heightened expectations that large corporations will serve the interests of all stakeholders and not just shareholders.”
- 79% of executives acknowledge the increased importance placed on employee health and wellbeing in the past two years.
- 77% of respondents agree that employee engagement is equally as essential as profitability when driving performance outcomes .
- 64% of business leaders surveyed say they have a well-established purpose set out in a formal mission statement .
- 61% of respondents are moving toward social purpose by generating value through sustainable profits while minimizing harm.
- 54% of respondents say they have established hybrid working—WFH versus office—schedules
- 53% of respondents said cybersecurity is the most important technology tool for social purpose implementation, with 44% citing artificial intelligence (AI) as the second most important tool .
Post-pandemic, people and the planet rather than solely profit are becoming increasingly important for organizations of all sizes, and digital technologies will play a central role in creating a ‘new normal.’ A large majority of CEOs surveyed say that the pandemic has increased the importance of social purpose and given prominence to those who lead with purpose.
Business leaders acknowledge that staff need support during this period of significant change, and organizations that fail to act run the risk of losing their competitive advantage. Most respondents highlight the substantial positive impacts on financial and non-financial business outcomes.
About This Research
This research was conducted in June/July 2021 among CEOs across 15 countries, who participated in an online survey that considers how organizations better support employee wellbeing and change management and highlights the importance of improved internal and external communication. It uncovers the most valuable tools and tips for social purpose implementation while also analyzing the most significant challenges. The respondents represent companies operating in 10 major industries; about one-quarter of these organizations report annual revenues of US$10 billion or more, and approximately one-third generate between $500 million and $1 billion. The survey asked CEOs about how they viewed their organization’s role in society, social impact strategies, stakeholders involved, and how these strategies have been impacted—and driven—by the Covid-19 pandemic. The survey follows a similar one conducted in 2020, entitled Building Back with Purpose , enabling assessment of emerging trends. Read the latest research, please download the white paper .
About WSJ Intelligence
WSJ Intelligence, a unit of The Wall Street Journal's advertising department, conducts bespoke and secondary research for brands and client brands of The Wall Street Journal | Barron's Group. Through rigorous analysis, WSJ Intelligence provides insights that are relevant, timely, and reliable. The Wall Street Journal news organization was not involved in the creation of this content.
About NTT
NTT believes in contributing to society through our business operations. We help people, clients and communities move confidently into the digital future and shape a better world. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks. As a top-five global technology and business solutions provider, our diverse team of over 300,000 people operates in 80-plus countries and regions and delivers services to over 190 of them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211017005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
